Progress in Drug Research for Non-Hodgkin’s Lymphoma

Non-Hodgkin's lymphoma (NHL) is a group of highly heterogeneous hyperproliferative hematological tumors of the lymphatic system. With the deepened understanding of molecular mechanism of pathogenesis, new immunotherapies and small molecule drugs based on different molecular mechanisms continue to emerge, which have changed treatment mode of the disease, bringing more treatment options to high-risk, relapsed and refractory patients. In recent years, more and more attention has been paid to mobilizing autologous anti-tumor immunotherapy, including chimeric antigen receptor T cell therapy (CAR-T), antibody-drug conjugate (ADC) and bispecific antibody (BsAb). Especially, bispecific T cell engager (BiTE), which targets both tumor cells and effector T cells, has shown promising future of application. Novel immunotherapy targeting the tumor immune microenvironment and small molecule targeted drugs targeting the regulation of signaling pathways have become new options for the treatment of NHL. This article briefly reviews the current drug research progress and clinical application in the field of NHL.